Beta Bionics Q4 2025 revenue $32.1M (+57% YoY); guides FY2026 $130-135M

Beta Bionics, Inc.

2025-FY EPS reported -$1.81 revenue$100,251,000

Net sales $32.1M in Q4 (+57% YoY); full year $100.3M (+54%). Installed base 35,011 users (+129%).
Gross margin 59% Q4 (up 179bps); FY gross margin 55.4%. Net loss $13.5M Q4 (improved from $18.1M).
2026 guidance: revenue $130M-$135M; PBP channel 36-38% of new starts; gross margin 55.5%-57.5%.
Bihormonal system Phase 2a first-in-human trial completed in New Zealand; additional Phase 2a expected H1 2026.
Cash $264.7M as of Dec 31, 2025. New patient starts up 37% Q4 to 5,592.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.